The first involved a 63-year-old female patient with cervical adenocarcinoma and ErbB2 overexpression identified by IHC, who achieved a best RECIST response of PR (−65%) by the end of cycle 6 and maintained this PR for >14 months. The gene discussed is ERBB2; the disease is cervical adenocarcinoma.